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Dehydroabietic acid (DHA) is a naturally occurring diterpenic
resin acid, which can be easily isolated from commercialdisproportionated rosin by crystallization of the 2-aminoetha-
nol salt. DHA can be used in the ﬁeld of synthetic chemistry
because of its unique characteristics. DHA and a number of
its derivatives have been reported to possess a broad spectrum
of biological properties such as antimicrobial, antitumor, anti-
viral, antioxidant, gastroprotective and K+ channel-opening
activities [1–6].
Amides are important organic compounds with a wide
range of applications [7,8]. The stablility of amide bond makes
the amide function important to synthetic chemists especially
in peptides and lactam synthesis, in which the formation of
amide bonds is crucial. Some derivatives of amides exhibit
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antifungal, and antibacterial [9–13].
The synthesis of compounds incorporated with a 1,3,4-thia-
diazole ring has attracted widespread attention due to its
diverse pharmacological properties such as antimicrobial
[14,15], antifungal [16], anti-inﬂammatory [17], antitubercular
[18], herbicidal [19,20] and plant growth regulating activities
[21–24]. Although there are a number of antibiotics which
are commercially used in medicine, the synthesis of new com-
pounds is of vital importance due to the increase of drug resis-
tance. Moreover, it is important to obtain compounds with
higher bioactivity and lower toxic effect.
In this paper, a series of N-[5-dehydroabietyl-[1,3,4]
thiadiazol-2-yl]-aromatic amide derivatives were synthesized
from dehydroabietic acid with the aim of ﬁnding potent bioac-
tive compounds. The structures of these compounds were ver-
iﬁed by means of IR, MS, 1H NMR and elemental analysis. In
addition, the preliminary antimicrobial activity was tested. The
synthetic route of target compounds is shown in Scheme 1.
2. Experiment
2.1. General methods and materials
Dehydroabietic acid was separated and puriﬁed from dispro-
portionated rosin. All other chemicals were of reagent grade.
The IR spectra were taken on a Nicolet IS10 FT-IR
(Nicolet, Madison, USA) spectrophotometer. The 1H NMR
spectra were recorded on a Bruker AV-300 (Bruker, Karlsruhe,
Germany) nuclear magnetic resonance spectrometer with
DMSO as solvent and TMS as internal standard. The MS
spectra were taken on an Agilent-5973 (Agilent, Santa Clara,
USA) spectrophotometer. The melting points were determined
using WRS-2(Shanghai precision & scientiﬁc instrument Co.,
LTD, China) melting point apparatus. The elemental analysis
(C, H, N) was performed on a Vario EL-III (Elementar,
Hanau, Germany) elemental analyzer, their results were found
to be in good agreement with the calculated values (within
±0.8%). All reactions were traced by Thin layer chromatogra-
phy (TLC).
2.2. General synthetic procedure for 5-dehydroabietyl-2-azyl-
1,3,4-thiadiazole (1)
Dehydroabietic acid (0.05 mol) was reﬂuxed with thiosemicar-
bazide (0.05 mol) in the presence of phosphorus oxychloride
(15 ml) for 1 h. The reaction mixture was cooled and dilutedwith water and again reﬂuxed for 4 h. The reaction was mon-
itored by thin layer chromatography and ﬁltered after comple-
tion. The ﬁltrate was basiﬁed with potassium hydroxide and
the precipitate was ﬁltered off and then recrystallized from eth-
anol to give the desired compound 1. Gray white solid. Yield:
72.6%. Mp: 228.6–229.1 C. IR: = 3293, 3124, 2935, 2870,
1650,1497, 1459, 670 cm1. MS(ESI (+)) m/z: 356
(M+H+), 378 (M+Na+). 1H NMR (DMSO, 300 MHz):
d= 9.21 (s, 2H, –NH2–) 6.85–7.21 (m, 3H, Ar–H), 2.70–2.85
(m, 2H, –CH–), 1.72–2.61 (m, 10H, –CH2–), 1.14–1.67 (m,
12H, –CH3). Calc. for C21H29N3S, %: C, 70.94; H, 8.22; N,
11.82. Found, %: C, 70.50; H, 8.29; N, 11.52.
2.3. General synthetic procedure for N-[5-dehydroabietyl-
[1,3,4]thiadiazol-2-yl]-aromatic amide (2a–2e)
A solution of aryl chloride in 15 mL CH2Cl2 was added
dropwise to a solution of 10 mmol of compound 1 and
30 mmol triethylamine in 40 ml CH2Cl2 within 30 min at
temperature 0–5 C. The reaction mixture was then allowed
to warm to room temperature over 6 h and washed with water,
then dried with anhydrous MgSO4. The residue was puriﬁed
using silica gel chromatography [m(ethyl acetate)/m(petroleum
ether) = 10:1) to give compounds 2a–2e.
2.3.1. N-[5-dehydroabietyl-[1,3,4]thiadiazol-2-yl]-
benzamide(2a C28H33N3OS)
White solid. Yield: 85%. Mp: 184.6–185.5 C. IR: = 3149,
2955, 2866, 1667, 1601, 1581, 1494, 1451, 676 cm1. MS(ESI
(+)) m/z: 460 (M+H+), 482 (M+Na+). 1H NMR (DMSO,
300 MHz): d= 12.91(s, H, –CONH–), 7.49–8.08 (m, 5H,
Ar–H), 6.80–7.18 (m, 3H, Ar–H), 2.71–2.80 (m, 2H, –CH–),
2.02–2.69 (m, 10H, –CH2–), 1.41–1.98 (m, 12H, –CH3). Calc.
for C28H33N3OS, %: C, 73.16; H, 7.24; N, 9.14. Found, %:
C, 73.30; H, 7.58; N, 9.37.
2.3.2. N-[5-dehydroabietyl-[1,3,4]thiadiazol-2-yl]-
phenylacetamide (2b C29H35N3OS)
White solid. Yield: 80.5%. Mp: 161.8–162.3 C. IR: = 3152,
2922, 2859, 1694, 1603, 1495, 1453, 653 cm1. MS(ESI (+))
m/z: 474 (M+H+), 496 (M+Na+). 1H NMR (DMSO,
300 MHz): d= 12.63 (s, H, –CONH–), 7.14–7.30 (m, 5H,
Ar–H), 6.78–6.96 (m, 3H, Ar–H), 3.76 (s, 2H, –NHCO–
CH2–), 2.69–2.77 (m, 2H, –CH–), 2.30–2.63 (m, 10H, –
CH2–), 1.37–1.95 (m, 12H, –CH3). Calc. for C29H35N3OS,
%: C, 73.53; H, 7.45; N, 8.87. Found, %: C, 73.93; H,
7.83; N, 9.04.
Table 1 Experimental crystallographic data for compound
2b.
Empirical formula C29H35N3OS
Formula weight 452.56
Temperature 293 K
Wavelength 0.71073 A˚
Crystal system monoclinic space group C2
Cell dimensions a= 22.356(5) A˚
b= 11.868(2) A˚
c= 21.071(4) A˚
b= 103.60(3)o
Volume V= 5433.8(19) A˚3
Z 4
Density (calculated) 1.163 Mg/cm3
F(000) 2042
Crystal size 0.30 · 0.20 · 0.10 mm
Theta range for data collection 2.20–25.02
Index ranges 0 6 h 6 26, 14 6 k 6 14,
25 6 l 6 25
Reﬂections collected 10267
Independent reﬂections 9996(Rint = 0.060)
Data/restraints/parameters 9996/0/593
Goodness of ﬁt on F 0.986
Final R indices (I> 2r(I)) R= 0.073, wR= 0.191
Largest diﬀ. peak and hole 0.55 and 0.40 e A˚
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benzamide (2c C29H35N3OS)
White solid. Yield: 83.2%. Mp: 183.1–184.0 C. IR: = 3150,
2928, 2869, 1660, 1609, 1508, 1463, 681 cm1. MS(ESI (+))
m/z: 474 (M+H+), 496 (M+Na+). 1H NMR (DMSO,
300 MHz): d= 12.79 (s, H, –CONH–), 7.16–7.99 (m, 4H,
Ar–H), 6.81–6.98 (m, 3H, Ar–H), 2.70–2.81(m, 3H, Ar–
CH3), 2.36–2.67 (m, 2H, –CH–), 1.71–2.02 (m, 10H, –CH2–),
1.30–1.52 (m, 12H, –CH3). Calc. for C29H35N3OS, %: C,
73.53; H, 7.45; N, 8.87. Found, %: C, 73.76; H, 7.80; N, 8.89.
2.3.4. N-[5-dehydroabietyl-[1,3,4]thiadiazol-2-yl]-p-chloro
benzamide (2d C28H32ClN3OS)
White solid. Yield: 85%. Mp: 214.2–215.6 C. IR: = 3119,
2945, 2862, 1658, 1594, 1492, 1434, 678 cm1. MS(ESI (+))
m/z: 494 (M+H+), 516 (M+Na+). 1H NMR (DMSO,
300 MHz): d= 13.02(s, H, –CONH–), 7.55–8.09 (m, 4H,
Ar–H), 6.81–7.19 (m, 3H, Ar–H), 2.33–2.81 (m, 2H, –CH–),
1.71–2.01 (m, 10H, –CH2–), 1.42–1.52 (m, 12H, –CH3). Calc.
for C28H32ClN3OS, %: C, 68.06; H, 6.53; N, 8.50. Found,
%: C, 67.95; H, 6.72; N, 8.58.
2.3.5. N-[5-dehydroabietyl-[1,3,4]thiadiazol-2-yl]-p-nitryl
benzamide (2e C28H32N4O3S)
Yellow solid. Yield: 81.4%. Mp: 243.3–244.8 C. IR: = 3138,
2930, 2859, 1668,1604, 1526, 1494, 1436, 1343, 665 cm1.
MS(ESI (+)) m/z: 505 (M+H+), 527 (M+Na+). 1H NMR
(DMSO, 300 MHz): d= 13.41 (s, H, –CONH–), 8.25–8.35
(m, 4H, Ar–H), 6.81–7.19 (m, 3H, Ar–H), 2.33–2.79 (m, 2H,
–CH–, 1.71–2.01 (m, 10H, –CH2–), 1.26–1.51(m, 12H, –
CH3). Calc. for C28H32N4O3S, %: C, 66.64; H, 6.39; N,
11.10. Found, %: C, 66.58; H, 6.66; N, 11.21.
2.4. X-ray crystal structure determination
The crystal structure of 2b was determined by X-ray single
crystal diffraction. XRD data were collected on a Enraf–
NoniusCAD-4 diffractometer equipped with Mo Ka
(k= 0.71073 A˚) at 293 K. A single crystal suitable for determi-
nation was mounted inside a glass ﬁber capillary. The structure
of the title compound was solved by direct methods and re-
ﬁned by full-matrix least squares on F2. All the hydrogen
atoms were added in their calculated positions and all theTable 2 Selected bond lengths (A˚) and bond angles () for compou
Bond Dist. Bond
S(1)–C(21) 1.727(5) S(1)–C(20)
N(1)–C(20) 1.294(6) N(1)–N(2)
N(3)–C(22) 1.374(7) N(3)–C(21)
C(1)–C(2) 1.394(7) C(3)–C(4)
C(28)–C(29) 1.370(10)
Angle () Angle
C(21)–S(1)–C(20) 86.4(3) C(20)–N(1)–N(2)
C(22)–N(3)–C(21) 126.7(5) N(3)–C(22)–C(23)
O(1)–C(22)–N(3) 120.0(5) N(1)–C(20)–C(11)
C(11)–C(20)–S(1) 124.5(3) N(2)–C(21)–N(3)
N(3)–C(21)–S(1) 125.2(4)
Symmetry transformation: a: x,y+ 1,z; b: x,y,z+ 1/2; c: x,y+non-hydrogen atoms were reﬁned with anisotropic tempera-
ture factors. SHELXS 97 were used to solve he structure and
SHELTL were used to reﬁne the structure [25–27]. There are
two molecules and 0.25 water molecule in the empirical for-
mula. The crystallographic details are summarized in Table 1.
The selected bond lengths and angles are shown in Table 2.
2.5. Antibacterial activity
The antibacterial activity of chemicals was estimated by the
minimum inhibition concentration (MIC). The MIC of
compound was determined by the ﬂat panel double dilution
method. Test strain selection pathogenic bacteria are as
follows: Escherichia coli, Staphyloccocus aureus, Klebsiella
pneumoniae, Pseudomonas aeruginosa, Escherichia aerogenes,
and Staphyloccocus epidermidis. The samples were preparednd 2b.
Dist. Bond Dist.
1.734(5) O(1)–C(22) 1.192(6)
1.390(6) N(2)–C(21) 1.279(6)
1.385(7) C(11)–C(20) 1.525(7)
1.386 (8) C(24)–C(25) 1.363(10)
() Angle ()
111.6(4) C(21)–N(2)–N(1) 113.2(4)
113.8(5) O(1)–C(22)–C(23) 126.2(6)
120.8(4) N(1)–C(20)–S(1) 114.4(4)
120.3(5) N(2)–C(21)–S(1) 114.4(4)
1,z.
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121 C for 30 min. Duplicate twofold serial dilutions of each
sample were added into MH AGAR medium for ﬁnal concen-
tration of 2560, 1280, 640, 320, 160, 80, 40 and 20 mg/ml.
Some samples were prepared by decuple diluting method.
The cultured bacterium was diluted by sterile water to obtain
a bacterial suspension. The density of the organism suspension
was adjusted to 108 CFU/ml by adding sterile deionized water.
After inoculation, the plates were incubated at 37 C for 24 h.
The colonies were counted and the MIC values were obtained.
The MIC is deﬁned as the lowest concentration of antibiotic at
which there is no visible growth of the organism. Standard
compounds Bromogeramine and Ampicillin Sodium were
measured alone.
3. Results and discussion
3.1. Chemistry
Because POCl3 can be dissolved in water, the reaction must be
dry in the general synthetic procedure of 5-dehydroabietyl-2-
azyl-1,3,4-thiadiazole. The reaction process of N-[5-dehydroa-
bietyl- [1,3,4]thiadiazol-2-yl]-aromatic amide in dilute acid
hydrolysis reaction will not be complete. So acid binding
agents, such as sodium bicarbonate, sodium carbonate, three
ethylamine, pyridine, are needed to improve the reaction yield.
All the synthesized compounds were characterized by using
spectroscopic techniques like IR, MS, 1H NMR and elemental
analysis. The IR spectra of compounds 2(a–e) exhibited char-
acteristic moderate absorption bands at 2932–2867, 1755–1749
and 1660–1603 cm1 which attributed to the stretching vibra-
tions of the –CH3, –CH2, C‚O and C‚N, respectively. The
characteristic C‚C stretching bands at 1600–1450 cm1asso-
ciated with the aromatic rings were observed in all the target
compounds. In addition, compound 5d exhibited a character-
istic strong absorption band at 1098 cm1 attributed to the
stretching vibrations of the Ar–Cl; compound 5e exhibited
characteristic strong absorption bands at 1526 cm1,
1343 cm1 attributed to the symmetrical stretching vibrations
and the asymmetric stretching vibration of the –NO2. The
1H NMR spectra of all compounds 2(a–e) exhibited character-Figure 1 X-ray structuistic signals at 6.83–7.82 ppm assigned to the aromatic protons
and at 12.63–13.41 ppm assigned to the acylamino protons.
3.2. Structure analysis
Full crystallographic details of 2b have been deposited at the
Cambridge Crystallographic Data Center and allocated the
deposition number of CCDC 683542. White crystals of 2b suit-
able for X-ray analysis were obtained by solvent evaporation
under room temperature. Its single-crystal structure was deter-
mined by X-ray crystallography. Only one molecular structure
is shown in Fig. 1, in order to clearly see the structure of com-
pound 2b. As shown in Fig. 1, themolecular structure of 2b con-
tains four crystallographically unique six-membered rings: ring
A (C1–C6), ring B (C1,C6-C10), ringC (C10, C9, C11–C14) and
ring D (C24–C29). Their torsion angles show ring B and C exhi-
bit chair and half-chair conﬁguration, respectively, they form
trans ring junction with two methyl groups (C15, C16) in axis
positions. However, the six atoms in the other two six-mem-
bered rings are coplanar. The sum of O1–C22–N3, O1–C22–
C23 and N3–C22–C23 angles is 360, which indicates sp2
hybridization state of the C22 atom.Due to the p–p conjugating
effect, the C22–N3 bond (1.374 (7) A˚) is shorter than the typical
C–N bond (1.47 A˚) and approximates to the typical C‚Nbond
(1.35 A˚). Based on the shorter bond lengths of N1–N2
1.390(6) A˚, C11–C20 1.525(7) A˚, C21–N3 1.385(7) A˚ and
C20–S1 1.734(5) A˚, C21–S1 1.727(5) A˚ than ordinary N–N,
C–C, C–N and C–S single bond, and longer bond lengths of
C20–N1 1.294(6) A˚ and C21–N2 1.279(6) A˚ than ordinary
C–N double bond, we can conclude that conjugation occurs be-
tween the twoC–Ndouble bonds. The title compound is a chiral
molecule with three chiral centers in eachmolecule, in which C9,
C10 and C11 exhibit R-, S-, R- absolute stereo-conﬁguration,
respectively. From the viewof crystal packing (Fig. 2), it is found
thatweak inter-molecular p  p stacking interactions exist in the
structure.
3.3. Biological evaluation
Five newly synthesized compounds were screened for their
antibacterial activitives against six kinds of bacteria, namely,re of compound 2b.
Figure 2 The packing diagram of compound 2b the unit cell.
Table 3 Antimicrobial activities of the compounds 2(a–e) (lg/mL).
Compound A B C D E F ①
2a >256 256 >256 4 >256 64
2b >256 >256 >256 8 64 >256
2c >256 >256 >256 8 >256 >256
2d >256 >256 >256 8 >256 >256
2e >256 >256 >256 8 >256 >256
Bromogeramine 256 8 64 8 128 8
Ampicillin 64 4 64 >256 >256 8
A: Escherichia coli B: Staphyloccocus aureu C: Klebsiella pneumoniae D: Pseudomonas aeruginosa E: Escherichia aerogenes F: Staphyloccocus
epidermidis.
S262 Y. Cui et al.E. coli (CMCC-44102), S. aureus (CMCC-26003), K. pneumo-
niae (GIM-1.279), P. aeruginosa (CMCC-10104), E. aerogenes
(GIM-1.234) and S. epidermidis (CMCC-26069). Some of them
were compared to standard Bromogeramine and Ampicillin
Sodium. The MIC method [25] was used to assay the antibac-
terial activity. The results are summarized as MIC values in
lg/mL in Table 3.
Nevertheless, compound 2a showed efﬁcacious antibacte-
rial activity against Pseudomonas aeruginosa. The result impli-
cated that blockage of the interaction of the aromatic ring
group may be the main reason causing a decrease of the anti-
bacterial activity because of the steric hindrance of aromatic
ring para substituents. Therefore, changing the para substitu-
ents group of aromatic ring did not increase the antibacterial
activity of these N-[5-dehydroabietyl-[1,3,4] thiadiazol-2-yl]-
aromatic amide derivatives.
In conclusion, we have prepared a new series of
N-[5-dehydroabietyl-[1,3,4]thiadiazol-2-yl]- aromatic amide
derivatives. All compounds exhibit anti-bacterial activity
against Pseudomonas aeruginosa, and the minimum inhibition
concentration of these compounds is 4, 8, 8, 8, and 8 lg/mlrespectively. Comparing with the minimum inhibition concen-
tration of 8 lg/ml of the commercial compound bromoger-
amine and >256 lg/ml of Ampicillin Sodium, the
synthesized compounds obviously show anti-bacterial activity.4. Conclusion
In summary, a series of N-[5-dehydroabietyl-[1,3,4]thiadiazol-
2-yl]-aromatic amides derivatives were synthesized from dehy-
droabietic acid. Their structures were characterized by IR, 1H
NMR spectroscopy and elemental analysis. All compounds
exhibited highly effective activities against Pseudomonas aeru-
ginosa. Compound 2b showed efﬁcacious antibacterial activi-
ties against E. aerogenes. Further investigation of this type of
compound is also in progress now.Acknowledgements
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